[Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
Chronic Immune Thrombocytopenic Purpura (cITP) has become a field of multiple therapeutic assays. More than 20 types of treatment have been developed to obtain a favorable and prolonged platelet response. The treatment of cITP is oriented to inhibit the antiplatelet antibodies production by interference with the macrophage of the reticulum endothelial system and a blockade of the antigenic response with a decrease in the amplification of the immunological response. Steroids of the glucocorticoids type and splenectomy constitute the first line of treatment. Failure of these treatments leads to the use of second line drugs such as non steroid immuno-supressors and the immunoglobulins type IgG and anti-D. Therapeutic assays with others immunomodulators have been reported. The introduction of new drugs destined to increase the megakaryocytic bone marrow platelet production, has opened a new way to treat the cITP. However, the splenectomy remains as the simplest, safest and most effective treatment in cITP. The principal criteria does not have to be focused on obtaining a normal platelet count, but to reach safe hemostatic levels in absence of hemorrhage, for a prolonged time. On the other hand, despite the persistence of thrombocytopenia, the hematologist can choose to maintain the patient with no treatment and with only a strict clinical observation. It is obvious that the cost-benefit from the different treatments is inclined towards those of lower cost and minimal secondary effects.
Instituto de Investigaciones Clínicas "Dr. Américo Negrette", Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela. g_vizcaino@hotmail.com
Gilberto
G
Vizcaíno
María
M
Diez-Ewald
Jennifer
J
Vizcaíno-Carruyo
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D016824:Antigens, Human Platelet / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000276:immunology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D003622:Dapsone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018448:Models, Immunological; D018716:Molecular Mimicry; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D013156:Splenectomy; D034061:Thrombopoiesis / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D016824:Antigens, Human Platelet; D001323:Autoantibodies; D001565:Benzoates; D006834:Hydrazines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D011720:Pyrazoles; D003622:Dapsone; C520809:eltrombopag